Logo image of TTOO

T2 BIOSYSTEMS INC (TTOO) Stock Fundamental Analysis

NASDAQ:TTOO - Nasdaq - US89853L3024 - Common Stock - Currency: USD

0.134  -0.06 (-31.07%)

After market: 0.12 -0.01 (-10.45%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to TTOO. TTOO was compared to 561 industry peers in the Biotechnology industry. TTOO may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, TTOO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year TTOO has reported negative net income.
TTOO had a negative operating cash flow in the past year.
In the past 5 years TTOO always reported negative net income.
TTOO had a negative operating cash flow in each of the past 5 years.
TTOO Yearly Net Income VS EBIT VS OCF VS FCFTTOO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

TTOO has a Return On Assets of -237.55%. This is amonst the worse of the industry: TTOO underperforms 92.36% of its industry peers.
Industry RankSector Rank
ROA -237.55%
ROE N/A
ROIC N/A
ROA(3y)-135.6%
ROA(5y)-134.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TTOO Yearly ROA, ROE, ROICTTOO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TTOO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TTOO Yearly Profit, Operating, Gross MarginsTTOO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

TTOO does not have a ROIC to compare to the WACC, probably because it is not profitable.
TTOO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TTOO has more shares outstanding
TTOO has a better debt/assets ratio than last year.
TTOO Yearly Shares OutstandingTTOO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
TTOO Yearly Total Debt VS Total AssetsTTOO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

TTOO has an Altman-Z score of -55.84. This is a bad value and indicates that TTOO is not financially healthy and even has some risk of bankruptcy.
TTOO has a Altman-Z score of -55.84. This is amonst the worse of the industry: TTOO underperforms 95.03% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -55.84
ROIC/WACCN/A
WACC7.42%
TTOO Yearly LT Debt VS Equity VS FCFTTOO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 0.40 indicates that TTOO may have some problems paying its short term obligations.
TTOO has a worse Current ratio (0.40) than 94.49% of its industry peers.
TTOO has a Quick Ratio of 0.40. This is a bad value and indicates that TTOO is not financially healthy enough and could expect problems in meeting its short term obligations.
TTOO's Quick ratio of 0.24 is on the low side compared to the rest of the industry. TTOO is outperformed by 96.45% of its industry peers.
Industry RankSector Rank
Current Ratio 0.4
Quick Ratio 0.24
TTOO Yearly Current Assets VS Current LiabilitesTTOO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 97.25% over the past year.
The Revenue for TTOO has decreased by -30.16% in the past year. This is quite bad
Measured over the past years, TTOO shows a decrease in Revenue. The Revenue has been decreasing by -7.29% on average per year.
EPS 1Y (TTM)97.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.59%
Revenue 1Y (TTM)-30.16%
Revenue growth 3Y-26.52%
Revenue growth 5Y-7.29%
Sales Q2Q%34.85%

3.2 Future

The Earnings Per Share is expected to grow by 14.64% on average over the next years. This is quite good.
Based on estimates for the next years, TTOO will show a very strong growth in Revenue. The Revenue will grow by 54.19% on average per year.
EPS Next Y83.26%
EPS Next 2Y39.13%
EPS Next 3Y25.19%
EPS Next 5Y14.64%
Revenue Next Year51.43%
Revenue Next 2Y81.66%
Revenue Next 3Y68.18%
Revenue Next 5Y54.19%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TTOO Yearly Revenue VS EstimatesTTOO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M 80M 100M
TTOO Yearly EPS VS EstimatesTTOO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 -5K -10K -15K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TTOO. In the last year negative earnings were reported.
Also next year TTOO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TTOO Price Earnings VS Forward Price EarningsTTOO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TTOO Per share dataTTOO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

TTOO's earnings are expected to grow with 25.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.13%
EPS Next 3Y25.19%

More info and screens

0

5. Dividend

5.1 Amount

TTOO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

T2 BIOSYSTEMS INC

NASDAQ:TTOO (2/11/2025, 8:00:01 PM)

After market: 0.12 -0.01 (-10.45%)

0.134

-0.06 (-31.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)05-05 2025-05-05
Inst Owners3.18%
Inst Owner Change-89.33%
Ins Owners0.1%
Ins Owner Change0%
Market Cap3.76M
Analysts43.33
Price Target5.1 (3705.97%)
Short Float %0.1%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-19.68%
Min Revenue beat(2)-30.5%
Max Revenue beat(2)-8.87%
Revenue beat(4)1
Avg Revenue beat(4)-7.69%
Min Revenue beat(4)-30.5%
Max Revenue beat(4)26.29%
Revenue beat(8)1
Avg Revenue beat(8)-6.63%
Revenue beat(12)3
Avg Revenue beat(12)-6.67%
Revenue beat(16)6
Avg Revenue beat(16)-2.71%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.49
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.82
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-1.31
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0.27
BVpS-0.42
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -237.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-135.6%
ROA(5y)-134.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.4
Quick Ratio 0.24
Altman-Z -55.84
F-Score3
WACC7.42%
ROIC/WACCN/A
Cap/Depr(3y)30.32%
Cap/Depr(5y)34.46%
Cap/Sales(3y)1.94%
Cap/Sales(5y)3.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)97.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%83.59%
EPS Next Y83.26%
EPS Next 2Y39.13%
EPS Next 3Y25.19%
EPS Next 5Y14.64%
Revenue 1Y (TTM)-30.16%
Revenue growth 3Y-26.52%
Revenue growth 5Y-7.29%
Sales Q2Q%34.85%
Revenue Next Year51.43%
Revenue Next 2Y81.66%
Revenue Next 3Y68.18%
Revenue Next 5Y54.19%
EBIT growth 1Y12.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y27.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y27.02%
OCF growth 3YN/A
OCF growth 5YN/A